- Home
- CISO vs NEUP Comparison
CISO vs NEUP Comparison
Compare CISO & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CISO
- NEUP
- Stock Information
- Founded
- CISO 2015
- NEUP 1996
- Country
- CISO United States
- NEUP United States
- Employees
- CISO N/A
- NEUP N/A
- Industry
- CISO Computer Software: Prepackaged Software
- NEUP
- Sector
- CISO Technology
- NEUP
- Exchange
- CISO Nasdaq
- NEUP Nasdaq
- Market Cap
- CISO 44.2M
- NEUP 9.3M
- IPO Year
- CISO N/A
- NEUP N/A
- Fundamental
- Price
- CISO $0.81
- NEUP $6.65
- Analyst Decision
- CISO
- NEUP Strong Buy
- Analyst Count
- CISO 0
- NEUP 1
- Target Price
- CISO N/A
- NEUP $21.00
- AVG Volume (30 Days)
- CISO 6.3M
- NEUP 24.5K
- Earning Date
- CISO 05-15-2025
- NEUP 05-20-2025
- Dividend Yield
- CISO N/A
- NEUP N/A
- EPS Growth
- CISO N/A
- NEUP N/A
- EPS
- CISO N/A
- NEUP 0.00
- Revenue
- CISO $29,887,603.00
- NEUP $15,662,715.00
- Revenue This Year
- CISO N/A
- NEUP N/A
- Revenue Next Year
- CISO N/A
- NEUP N/A
- P/E Ratio
- CISO N/A
- NEUP $2.14
- Revenue Growth
- CISO N/A
- NEUP N/A
- 52 Week Low
- CISO $0.26
- NEUP $2.90
- 52 Week High
- CISO $3.84
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- CISO 43.69
- NEUP N/A
- Support Level
- CISO $0.97
- NEUP N/A
- Resistance Level
- CISO $1.49
- NEUP N/A
- Average True Range (ATR)
- CISO 0.29
- NEUP 0.00
- MACD
- CISO -0.04
- NEUP 0.00
- Stochastic Oscillator
- CISO 14.42
- NEUP 0.00
About CISO CISO Global Inc.
CISO Global Inc provides cybersecurity services. The services are used to protect client's data, financial information, intellectual property, and business reputation. The services include penetration testing, security remediation, compliance auditing, vulnerability assessment, and others. Geographically, the company operates in U.S., Chile and All other countries. The maximum revenue is generated from U.S.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.